Preparation, Relative Toxicity, Chemotherapeutic Activity, and Pharmacokinetics of Liposomal SJA-95: A New Polyene Macrolide Antibiotic

References

• A. Adedoyin, C. E. Swenson, A. Hellmann, D. Radowska, G. Horwith, A. S. Janoff, and et al (2000). A pharmacokinetic study of amphotericin-B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob. Ag. Chemother. 44 (10):2900–2902.
   PubMedGoogle Scholar
• T. M. Allen. (1997). Liposomes: opportunities in drug delivery. Drugs 54:8–14.
   PubMed Web of Science ®Google Scholar
• T. M. Allen, and C. Hanson. (1991). Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochem. Biophys. Acta. 1068 (2):133–141.
   PubMedGoogle Scholar
• L. Berestein. (1989). Liposomes in infectious diseases: present and future. Curr. Clin. Top. Infect. Dis. 10:241–253.
   PubMedGoogle Scholar
• K. K. Chakraborty, and S. R. Naik. (2000). In situ liposomal preparation containing amphotericin B: related toxicity and tissue diposition studies. Pharm. Dev. Tech. 5:543–553.
   PubMed Web of Science ®Google Scholar
• K. K. Chakraborty, and S. R. Naik. (2001). Pharmacokinetic studies of in situ liposomal preparation containing amphotericin B complex with different chemically modified β-cyclodextrins. J. Lip. Res. 11 (1):1–14.
   Google Scholar
• K. K. Chakraborty, and S. R. Naik. (2003). Therapeutic and hemolytic evaluation of in situ liposomal preparation containing amphotericin B complexed with different chemically modified β-cyclodextrins. J. Pharm. Pharmceut. Sci. 6 (2):231–237.
   PubMedGoogle Scholar
• S. K. Desai, and S. R. Naik. (2008). Probable mechanism(s) of antifungal activity of SJA-95, a heptaene polyene antibiotic. Ind. J. Pharm. Sci. 270:165–169.
   Google Scholar
• R. D. Diamond. (1988). Fungal surfaces: effects of interactions with phagocytic cells. Rev. Infect. Dis. 2:428–431.
   Google Scholar
• M. A. Dietrich. (2004). New advances in fungal pharmacotherapy: voriconazole and caspofungin Inet Ce 221–146–04–069–H01. http://www.Inetce.com(pdf).
   Google Scholar
• M. Gibaldi. (2005). Compartmental and noncompartmental pharmacokinetics. In: Biopharmaceutics and Clinical Pharmacokinetics, 4th ed. Hyderabad, India: Pharma Book Syndicate, pp 14–23.
   Google Scholar
• J. Harindran, K. K. Chakraborty, and S. R. Naik. (1999). Preparation, relative toxicity, and therapeutic efficacy in mice and rats of liposomal HA–1–92 (a new oxohexaene polyene macrolide antibiotic). J. Pharm. Pharmacol. 51:771–776.
   PubMed Web of Science ®Google Scholar
• D. J. Hoban, G. G. Zhanel, and J. A. Karlowsky. (1999). In vitro susceptibilities of Candida and Cryptococcus neoformans from blood cultures and neutropenic patients. Antimicrob. Ag. Chemother. 43 (6):1463–1464.
   PubMedGoogle Scholar
• V. L. Kan, J. E. Bennett, M. A. Amantea, M. C. Smolkis, E. McManus, and D. M. Grasela. (1991). Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. J. Infect. Dis. 164:408–412.
   Google Scholar
• V. E. Khutorsky. (1992). Structure of amphotericin B–cholesterol complex. Biochim. Biophys. Acta. 1108:123–127.
   PubMed Web of Science ®Google Scholar
• J. W. Lee, M. A. Amantea, P. A. Franchis, E. E. Navarro, J. Bacher, P. A. Pizzo, and et al (1994). Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (Ambisome) in rabbits. Antimicrob. Ag. Chemother. 38 (4):713–718.
   PubMedGoogle Scholar
• R. I. Leher. (1966). Antifungal effects of peroxidase systems. J. Bacteriol. 99:361–365.
   Google Scholar
• J. T. Litchfield, and F. A. WilcoxonJr.. (1949). Simplified method of evaluating dose effects experiments. J. Pharmacol. Exp. Ther. 96:99–113.
   PubMed Web of Science ®Google Scholar
• S. de Marie, R. Janknegt, and I. A. J. M. Bakker-Woudenberg. (1994). Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chem. 33:907–916.
   PubMedGoogle Scholar
• B. McCormack, and B. Gregoriadis. (1996). Comparative Studies of the fate of free and liposome-entrapped hydroxypropyl-β-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery. Biochem. Biophys. Acta. 1291:237–244.
   PubMed Web of Science ®Google Scholar
• S. R. Naik, S. K. Desai, R. K. Nanda, and M. S. Narayanan. (2007). Fermentation, isolation, purification, and biological activity of SJA-95, a heptaene polyene macrolide antibiotic produced by Streptomyces sp. strain S-24. Arzneimittel-Forschung Drug Res. 57 (3):171–179.
   PubMedGoogle Scholar
• L. E. Nicolle, C. Rotstein, A. M. Bourgault, G. St. Germain, and G. Garber. (1998). The Canadian Infections Invasive Fungal Registry. Invasive fungal infections in Canada from 1992 to 1994. Can. J. Infect. Dis. 9:347–352.
   PubMedGoogle Scholar
• S. Perrett, M. Golding, and W. P. Willians. (1991). A simple method for the preparation of liposomes for pharmaceutical application: characterization of the liposomes. J. Pharm. Pharmacol. 43:154–161.
   PubMed Web of Science ®Google Scholar
• R. P. Rapp, P. O. Gubbuns, and M. E. Evans. (1997). Amphotericin B lipid complex. Ann. Pharmacother. 31:1174–1186.
   PubMedGoogle Scholar
• K. Richardson, K. W. Brammer, M. S. Marriott, and P. F. Troke. (1985). Activity of UK-49, 858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob. Agents Chemother. 27:832–835.
   PubMed Web of Science ®Google Scholar
• J. H. Senior. (1987). Fate and behaviour of liposomes in vivo: a review of controlling factors. CRC Crit. Rev.Ther. Drug Car. Sys. 3:123–193.
   PubMed Web of Science ®Google Scholar
• K. L. Therese, R. Bagyalakshmi, H. N. Madhavan, and P. Deepa. (2006). In vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fluconazole, and ketoconazole against ocular fungal isolates. Ind. J. Microbiol. 24 (4):273–279.
   Google Scholar
• A. K. Uppadhyay, S. K. Jain, and V. K. Dixit. (1997). Long circulation liposomes: an overview. Ind. Drugs 34 (9):483–487.
   Google Scholar